Thanks I follow them as well and almost jumped in at $1.08 per share. My only reservation is that its very thinly traded at this time and I'm not currently interested in OTC stocks.
I'm combing thought the conference call looking for the jewels to add to our update thread. http://edge.media-se...ofd5ndv8/lan/en
I pulled a few of Frank Jaksch's comments;
"We are preparing to start our second human study on nicotinamide riboside. The first study was a single dose administration which demonstrated that even a single dose of NIAGEN or NR was enough to show an increase of NAD. The second study will have a larger patient population and will be held over a longer period of time. Again monitoring not only the effects of nicotinamide riboside as an NAD or an effective NAD precursor, but will also be looking at several therapeutic end points that may result from increasing NAD with NR.
In Q2 we also announced a collaborative study, a human clinical study on NIAGEN with the University of Colorado in Boulder. Dr. Doug Seals will investigate the effects of NIAGEN on physical function of metabolism and healthy adults aged 45 to 79 years old. This placebo controlled double blind randomized crossover study will assess the potential benefits of daily NIAGEN supplementation over a course of six weeks. End points that will be assessed in the study include physical function, cardiorespiratory fitness and overall metabolism.
ChromaDex providing the NIAGEN supplements for the study along with the match placebo pills or control pills and ChromaDex is awarded a $100,000 research to Dr. Martin's postdoc research at Seals, Dr. Seal's lab, which will fund approximately 25% of the cost of the study." . . .
"We have seen an increased interest from multiple sources from the media regarding NR. We've also seen an increased interest in media attention to high profile published research studies. To highlight a couple of recent examples of that, Scientific American recently published an article by David Stipp who is actually a former Wall Street Journal writer. The article brought attention to the importance of NAD and the importance of both NR and pterostilbene essentially to NAD metabolism." . . . LongeCity Post Beyond Resveratrol: The Anti-Aging NAD Fad
"NAD is a lynch pin of energy metabolism among other roles and it's . . . its diminishing level with age is been implicated in mitochondrial deterioration. Supplements containing nicotinamide riboside, a precursor to NAD might be able to boost NAD levels and the article highlighted that point, which is important for us.
The article also reasserted ChromaDex's firstcomer status in the NAD game, by announcing that it conducted a clinical trial demonstrating a single dose of NR resulted in statistically significant increases of NAD. And it was also sorted as one would say, a sidebar important piece but the article also highlighted pterostilbene which is our first ingredient.
David Stipp has a fairly extensive background writing on science, medicine and aging since 1982 for Scientific American, the Wall Street Journal, Fortune, New York Times and many other publications as well. In 2014, he won an award for American Aging Associations Excellence in Journalism award. So having an article, a high profile article come out not only in Scientific American but from such a high profile author that had a previous history in writing about aging was important for ChromaDex. And we expect that type of pick up in the future as well."
"Cockayne syndrome for those of you know may not know what it is, it's a rare pediatric orphan disease, these kids suffer from a genetic abnormality that causes this accelerated aging condition. The researchers concluded that NR promise it's potential therapy for the disease as well as for other age related nerve generative conditions. We believe there is an immediate opportunity for pursue NR as a pharmaceutical therapy for treating Cockayne syndrome. We are currently preparing to file applications for both IND any orphan designation with the FDA."
They went into pTeroPure pterostilbene and something called
anthocyanins which are plant pigments which they are making cheaply from a special variety of corn.
Then they went into the stock analyst questions. I thought there might be some questions related to the recent clinical study but there were none.
There was one guy who asked about inflammation and NR, an analyst with Kay Associates. He asked "Have there been studies that showed that NR has anti-inflammatory effects?" I thought the question might be handled by Frank Jaksch or someone more associated with the comparative B3 research but the question was taken by the companies Chief Financial Officer who said; "Well, we haven't focused on the anti-inflammatory side of things, there is some evidence that shows that there is some impact potentially on inflammation but that’s not a primary focus for us."
I don't want to say they missed the boat on inflammation but since B3's other cousin NAM has been heavily studied in this regard they could have been more enthusiastic in at least saying it warranted further investigation. But instead they said its; "not a primary focus for us." I get the feeling they want to push the things that are unique to this B3 analog, not what it has in common with its cousin.
They are doing better quarter by quarter but still maintain considerable debt. They got called out on their employee stock option plan but more and more companies are going this direction, awarding these incentives to hold employees. I will not get into the quarterly numbers as we are not concentrating on this companies stock but rather its sustainability in future to provide us product and published medical details. Both seem to be in the future cards.
That's my short take on the conference call, wished I could have asked a few questions myself but I'd already hit the road for the office by the time they got to those and I'm not a stock analyst.
Edited by Bryan_S, 20 August 2015 - 06:21 AM.
This topic is locked
